CTI BioPharma Corp  

(Public, NASDAQ:CTIC)   Watch this stock  
Find more results for CTIC
2.36
+0.07 (3.06%)
Real-time:   3:12PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.31 - 2.40
52 week 1.60 - 4.25
Open 2.33
Vol / Avg. 629,004.00/1.31M
Mkt cap 341.67M
P/E     -
Div/yield     -
EPS -0.52
Shares 149.93M
Beta 1.19
Inst. own 29%
Oct 29, 2014
Q3 2014 CTi Biopharma Corp Earnings Call - 4:30PM EDT - Add to calendar
Oct 29, 2014
Q3 2014 CTi Biopharma Corp Earnings Release - 4:00PM EDT - Add to calendar
Sep 17, 2014
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI� - Webcast
Aug 4, 2014
Q2 2014 CTI BioPharma Corp Earnings Conference Call - Webcast
Aug 4, 2014
Q2 2014 CTi Biopharma Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -2046.09% -125.58%
Operating margin -1985.70% -119.75%
EBITD margin - -114.69%
Return on average assets -171.49% -52.02%
Return on average equity -624.31% -124.54%
Employees 106 -
CDP Score - -

Address

Suite 600 3101 Western Avenue
SEATTLE, WA 98121
United States - Map
+1-206-2827100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company is concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. The Company is primarily focused on commercializing PIXUVRI (pixantrone) in the European Union for multiplies relapsed or refractory aggressive non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial of pacritinib for the treatment of myelofibrosis. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects.

Officers and directors

Phillip M. Nudelman Ph.D. Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
James A. Bianco M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Louis A. Bianco Executive Vice President, Finance and Administration, and Chief Governance Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jack W. Singer M.D. Interim Chief Medical Officer, Executive Vice President, Global Medical Affairs and Translational Medicine, and Chief Compliance Officer.
Age: 71
Bio & Compensation  - Reuters
Matthew J. Plunkett Ph.D. Executive Vice President, Corporate Development
Age: 42
Bio & Compensation  - Reuters
Nancy L. Boman Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs
Bio & Compensation  - Reuters
Monique M. Greer Senior Vice President of Corporate Communications and Investor Relations
Age: 47
Bio & Compensation  - Reuters
Karen Ignagni Director
Age: 60
Bio & Compensation  - Reuters
John H. Bauer Independent Director
Age: 73
Bio & Compensation  - Reuters
Vartan Gregorian Ph.D. Independent Director
Age: 79
Bio & Compensation  - Reuters